All treatments
Treatment
Kesimpta 20 mg solution for injection in pre-filled pen clinical trials
2 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic confirmatory (Phase III)
A single-arm, prospective, multicentre, open-label study to evaluate ofatumumab treatment effectiveness and patient-reported outcomes (PRO) in patients with relapsing multiple sclerosis (RMS) transitioning from fumarate-based RMS approved therapies or fingolimod.
This study looks at how well a medicine called Kesimpta works for people with a type of multiple sclerosis called relapsing multiple sclerosis (RMS). It also checks for side effects and how people feel on the treatment, especially those switching from other MS medicines.
For: relapsing multiple sclerosis (RMS)Poland · Bulgaria · Portugal - AuthorisedTherapeutic exploratory (Phase II)
A Phase 2, Open-Label, Randomized, Multicenter Study of KYV101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor T Cell (CD19 CAR T) Therapy, in Subjects with Refractory Primary and Secondary Progressive Multiple Sclerosis (KYSA-7)
This study is testing a new type of cell therapy called KYV101 for people with serious forms of multiple sclerosis (MS) that are getting worse. It compares this new treatment with existing MS medications to see how well it works and if it's safe.
For: Primary or Secondary Progressive Multiple SclerosisGermany · Italy · Belgium